Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Acromegaly: what to do with medical treatment during pregnancy and the options available today.
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
If you missed this fantastic event, here is an on-demand video you can watch at your leisure. In this second installment of the Ionis’ Rare Disease Webinar series, panelists discuss acromegaly, a condition in which
On Thursday, January 21, 2021, there is a virtual FDA Externally Led Patient-Focused Drug Development (PFDD) meeting organized by the Acromegaly Community, a leading patient advocacy organization in the US. To learn more about
During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients. From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr.
Important changes in telehealth visit regulations provide an excellent opportunity for patients to receive consultations from highly experienced specialists in pituitary disease. Read on! On Monday, November 16, 2020, doctors Lewis Blevins and Sandeep Kunwar